Narciclasine as a Novel Therapeutic Target for Pulmonary Arterial Hypertension: Addressing Glycosylation in Disease Pathophysiology. - Vienna 2024

Novel aspects in pulmonary hypertension pathobiology

Chair(s): Christina A. Eichstaedt, Andrea Olschewski

Session type: Poster session

Narciclasine as a Novel Therapeutic Target for Pulmonary Arterial Hypertension: Addressing Glycosylation in Disease Pathophysiology.

Fran?ois Potus

EVENTS HOME

Abstract

Previous presentation

Next presentation

Session content

IL-6 regulates GATA6 gene promoter methylation by activating the JAK2/STAT3 signaling pathway to promote PASMCs proliferation

Weijia Liu

Poster

Abstract

Plexiform lesions in human explant lungs with end-stage pulmonary arterial hypertension: µCT analysis

Gitte Aerts

Poster

Abstract

Exploring P300/CBP as therapeutic targets for pulmonary arterial hypertension and right ventricular failure

Alice Bourgeois

Poster

Abstract

Narciclasine as a Novel Therapeutic Target for Pulmonary Arterial Hypertension: Addressing Glycosylation in Disease Pathophysiology.

Fran?ois Potus

Abstract

Increased DNA Methylation: A Potential Therapeutic Target in Pulmonary Arterial Hypertension

Reem El Kabout

Abstract

LncRNA MIR210HG promotes phenotype switching of pulmonary arterial smooth muscle cells through autophagy-dependent ferroptosis pathway

Ran Wang

Abstract

Pulmonary hypertension in patients carrying FLNA loss-of-function variants

Laura Stourm

Poster

Abstract

Unlocking the Potential of Genetic Research in Pulmonary Arterial Hypertension: Insights from Clinicians, Researchers and Study Team

Emilia Maria ?wietlik

Poster

Abstract

Understanding what drives Genetic Study Participation: Perspectives of Patients, Carers, and Relatives

Emilia Maria ?wietlik

Poster

Abstract

Pathogenic variants of genes associated with pulmonary arterial hypertension (PAH): Insights from Trans-Omics for Precision Medicine (TOPMed) study participants

Vasile Foris

Poster

Abstract

Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: An international multicentre study

Julien Grynblat

Poster

Abstract

Glycoprotein IIb/IIIa-ICAM-1 mediated platelet-endothelial adhesion aggravates pulmonary hypertension

Bai Qianwen

Poster

Abstract

Identification of integrin a5b1 inhibition as a potentially disease-modifying approach for the treatment of pulmonary arterial hypertension

Monica Montesinos

Poster

Abstract

Role of ATP Citrate Lyase (ACLY) in Vascular Remodeling

Yann Grobs

Abstract

Reduced SOX17 in HPAECs drives CXCL10/11 upregulation and CXCR3-dependant lymphocyte migration in vitro

Abdul Mahomed

Ifan Jenkin

Poster

Abstract

Aurora kinase B: A New Therapeutic Target in PAH

Sarah-eve Lemay

Poster

Abstract

Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells

Soni Savai Pullamsetti

Poster

Abstract

Utilising self-similarity to model the morphometry of the pulmonary arteries

Atefeh Rahimi

Poster

Abstract

Late Breaking Abstract - A risk score including parenchymal lung disease improves risk stratification in Group 3 Pulmonary Hypertension

Krit Dwivedi

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}